Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Current Assets (2020 - 2025)

Universe Pharmaceuticals' Current Assets history spans 6 years, with the latest figure at $53.6 billion for Q3 2025.

  • On a quarterly basis, Current Assets rose 3.81% to $53.6 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $53.6 billion, a 3.81% increase, with the full-year FY2025 number at $53.6 billion, up 3.81% from a year prior.
  • Current Assets hit $53.6 billion in Q3 2025 for Universe Pharmaceuticals, up from $51.6 billion in the prior quarter.
  • Over the last five years, Current Assets for UPC hit a ceiling of $53.6 billion in Q3 2025 and a floor of $25.3 million in Q3 2023.
  • Historically, Current Assets has averaged $13.2 billion across 5 years, with a median of $51.1 million in 2021.
  • Biggest five-year swings in Current Assets: tumbled 100.0% in 2021 and later skyrocketed 204246.6% in 2024.
  • Tracing UPC's Current Assets over 5 years: stood at $50.5 million in 2021, then dropped by 17.78% to $41.5 million in 2022, then plummeted by 39.12% to $25.3 million in 2023, then skyrocketed by 204246.6% to $51.6 billion in 2024, then grew by 3.81% to $53.6 billion in 2025.
  • Business Quant data shows Current Assets for UPC at $53.6 billion in Q3 2025, $51.6 billion in Q3 2024, and $33.5 million in Q1 2024.